Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 12/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.44 |
| ▸ | PRKAB2 | O43741 | 6/20 | 0.43 |
| ▸ | PRKAG1 | P54619 | 6/20 | 0.43 |
| ▸ | PRKAA2 | P54646 | 6/20 | 0.43 |
| ▸ | PRKAA1 | Q13131 | 6/20 | 0.43 |
| ▸ | PRKAG3 | Q9UGI9 | 6/20 | 0.43 |
| ▸ | PRKAG2 | Q9UGJ0 | 6/20 | 0.43 |
| ▸ | PRKAB1 | Q9Y478 | 6/20 | 0.43 |
| ▸ | PDE2A | O00408 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24348328 | 0.96 | TMEM97 (0.46) | TMEM97SIGMAR1PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL24348472 | 0.85 | PDE2A (0.46) | TMEM97SIGMAR1PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL24348476 | 0.85 | TMEM97 (0.46) | TMEM97SIGMAR1PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL24348437 | 0.83 | MEN1 (0.43) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL24349664 | 0.80 | IGF1R (0.47) | TMEM97SIGMAR1PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL24349631 | 0.80 | MEN1 (0.41) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL24348478 | 0.80 | MEN1 (0.41) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL24348479 | 0.80 | PDE2A (0.46) | TMEM97SIGMAR1PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL24348435 | 0.79 | KDM4E (0.48) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL24348470 | 0.79 | MEN1 (0.40) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230329236-A1 | HERBICIDAL PYRIMIDINE DERIVATIVES | MOA Technology Limited (GB) | 2023-10-19 | — | — | US | disclosed |
| US-20230329236-A1 | HERBICIDAL PYRIMIDINE DERIVATIVES | MOA Technology Limited (GB) | 2023-10-19 | — | — | US | disclosed |
| WO-2022053803-A1 | HERBICIDAL PYRIMIDINE DERIVATIVES | MOA Technology Limited (GB) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230329236-A1 | HERBICIDAL PYRIMIDINE DERIVATIVES | DPYD, XDH, DHX35 | TMEM97 3314/4885SIGMAR1 1251/4885PRKAB2 3755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.